Biocon Limited (BOM:532523)
366.00
+3.65 (1.01%)
At close: Nov 20, 2026
Biocon Revenue
Biocon had revenue of 43.89B INR in the quarter ending September 30, 2026, with 2.17% growth. This brings the company's total for the last twelve months to 174.15B, up 5.70% year-over-year. In the fiscal year ending March 31, 2026, Biocon had annual revenue of 169.27B with 10.91% growth.
Revenue (ttm)
174.15B
Revenue Growth
+5.70%
P/S Ratio
3.41
Revenue / Employee
10.59M
Employees
16,447
Market Cap
593.35B
Revenue by Segment
Fiscal year ended Mar 31, 2026 See the full Biocon breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 169.27B | 16.65B | 10.91% |
| Mar 31, 2025 | 152.62B | 5.06B | 3.43% |
| Mar 31, 2024 | 147.56B | 35.82B | 32.05% |
| Mar 31, 2023 | 111.74B | 29.90B | 36.54% |
| Mar 31, 2022 | 81.84B | 10.41B | 14.57% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Biocon | 174.15B |
| Dishman Carbogen Amcis | 27.56B |
| Anthem Biosciences | 20.50B |
| OneSource Specialty Pharma | 16.86B |
| Concord Biotech | 11.70B |
| Blue Jet Healthcare | 10.96B |
| Supriya Lifescience | 8.79B |
| Panacea Biotec | 7.20B |
Biocon News
- 9 days ago - Kiran Mazumdar-Shaw Praises Youngster For 'Jarvis' Inspired Smart Home Assistant That Works Offline - NDTV
- 18 days ago - Biocon Transcript: Q2 26/27 - Transcripts
- 18 days ago - Biocon Quarterly report: Q2 2027 - Filings
- 18 days ago - Biocon Slides: Q2 2027 - Filings
- 4 weeks ago - Biocon Annual report - Filings
- 5 weeks ago - Biocon settles Roche's US patent lawsuit over proposed breast-cancer drug copy - Reuters
- 2 months ago - Biocon's Pertuzumab Biosimilar Receives Positive EMA CHMP Recommendation - Nasdaq
- 2 months ago - Biocon Signs Brazil Pertuzumab Deal With Bahiafarma And Bionovis - Nasdaq